Illustration: Sarah Grillo/Axios
AI drug discovery and development companies have emerged as one of the hottest areas of the wide-ranging life sciences industry.
Why it matters: As AI-focused biotechs proliferate, VC investors and M&A bankers are eyeing opportunities.
The big picture: Generative AI's promise to cut drug development timelines and costs appeals to pharma, which is staring down rising production costs, competition from China and changing public policy.
- Regulators are also embracing the technology, with the FDA announcing plans to incorporate AI into approval processes as it seeks efficiency alongside personnel downsizing.
- Gen AI's advent represents a major inflection point for drug innovation, says Sidd Bhattacharya, PwC head of AI, pharma and life sciences. "The fact that biotechs and pharma companies have access to very unique data sets — that is a core differentiator."
By the numbers: VC investment in AI-enabled health care and life sciences companies has surged since 2020, per PitchBook.
- While investment activity peaked in 2021 at $22 billion, it still grew year-over-year to $10.5 billion invested across 511 deals in 2024.
- Some of this year's largest deals include Google's Isomorphic Labs, which raised $600 million in March, and Pathos AI, which raised $365 million at a $1.6 billion valuation in May.
What's next: The growing sector will also likely see companies consolidate—as Recursion Therapeutics recently did — and others may shut down.
- AIX Ventures partner Krish Ramadurai's advice to biotech executives: "If you get to the point where you can't raise, go shop for a bunch of distressed assets. Gobble them up and then try to tweak it."
Between the lines: The strongest AI drug discovery companies are those using patient responder data, says Ramadurai, who has backed AI drug discovery company Insilico Medicine.
- "95% of animal data still doesn't translate to humans, but if you model off of human data, then you're coming in with a higher degree of certainty," he says.
Reality check: As helpful as AI is, it has yet to discover a novel molecule, Bhattacharya notes.
- "Human biology is extremely complicated," he says. Even still, "I have no doubt in my mind that we'll eventually get a novel molecule discovered by AI."
Yes, but: The technology is demonstrating value within some companies.
- Ryght AI is streamlining clinical trial processes.
- Tempus and Caris Life Sciences are enhancing cancer detection and treatment.
- Genesis Therapeutics is working with AI companies like Nvidia to harness AI to develop oncology and autoimmune treatments in house, as well as with pharma partners.
- "Through our partnerships, we can cast a much wider net, both in just the volume of diseases and drug targets we can work on, but also the therapeutic areas as well," says Genesis founder and CEO Evan Feinberg.
💭 Thought bubble: Using AI to develop a unique pipeline of promising drugs, rather than just a discovery platform, could prove the most important differentiator for companies.
